John P. Butler Akebia Therapeutics, Inc. (AKBA) insider trading activity

John P. Butler is CEO and President of Akebia Therapeutics, Inc.. Currently has a direct ownership of 2.04 Million shares of AKBA, which is worth approximately $3.39 Million. The most recent transaction as insider was on Feb 29, 2024, when has been sold 46,570 shares (Common Stock) at a price of $1.58 per share, resulting in proceeds of $73,580. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 2.04M

0% 3M change

30.32% 12M change

Total Value Held $3.39 Million

John P. Butler Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 29 2024	SELL Open market or private sale	$73,580 $1.58 p/Share	46,570 Reduced 2.23%	2,044,580 Common Stock
Feb 27 2024	SELL Open market or private sale	$57,354 $1.52 p/Share	37,733 Reduced 1.77%	2,091,150 Common Stock
Feb 01 2024	SELL Open market or private sale	$78,101 $1.68 p/Share	46,489 Reduced 2.14%	2,128,883 Common Stock
Jan 31 2024	BUY Grant, award, or other acquisition	-	603,500 Added 21.72%	2,175,372 Common Stock
Mar 01 2023	SELL Open market or private sale	$80,843 $0.88 p/Share	91,868 Reduced 5.53%	1,568,872 Common Stock
Feb 27 2023	SELL Open market or private sale	$31,291 $0.81 p/Share	38,632 Reduced 2.27%	1,660,740 Common Stock
Jan 31 2023	BUY Grant, award, or other acquisition	-	293,125 Added 14.71%	1,699,372 Common Stock
Mar 01 2022	SELL Open market or private sale	$117,121 $2.17 p/Share	53,973 Reduced 3.7%	1,403,247 Common Stock
Feb 28 2022	SELL Open market or private sale	$53,864 $2.15 p/Share	25,053 Reduced 2.11%	1,164,095 Common Stock
Feb 28 2022	BUY Grant, award, or other acquisition	-	293,125 Added 16.75%	1,457,220 Common Stock
Apr 01 2021	SELL Open market or private sale	$13,971 $3.4 p/Share	4,109 Reduced 0.36%	1,152,153 Common Stock
Mar 16 2021	BUY Grant, award, or other acquisition	-	39,520 Added 3.3%	1,156,262 Common Stock
Mar 01 2021	SELL Open market or private sale	$169,966 $3.4 p/Share	49,990 Reduced 4.28%	1,116,742 Common Stock
Feb 26 2021	BUY Grant, award, or other acquisition	-	237,400 Added 16.91%	1,166,732 Common Stock

Also insider at

ZYNE

Zynerba Pharmaceuticals, Inc. Healthcare

JPB

John P. Butler

CEO and President

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKBA shares.

Notify only if

Value

Insider Trading

Get notified when an Akebia Therapeutics, Inc. insider buys or sells AKBA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Akebia Therapeutics, Inc.

Track Activities on AKBA

Account